Herbein et al. Retrovirology 2010, 7:34
Macrophage signaling in HIV-1 infection
© 2010 Herbein et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
Georges Herbein*1, Gabriel Gras2, Kashif Aziz Khan1 and Wasim Abbas1
The human immunodeficiency virus-1 (HIV-1) is a member of the lentivirus genus. The virus does not rely exclusively on
the host cell machinery, but also on viral proteins that act as molecular switches during the viral life cycle which play
significant functions in viral pathogenesis, notably by modulating cell signaling. The role of HIV-1 proteins (Nef, Tat, Vpr,
and gp120) in modulating macrophage signaling has been recently unveiled. Accessory, regulatory, and structural HIV-
1 proteins interact with signaling pathways in infected macrophages. In addition, exogenous Nef, Tat, Vpr, and gp120
proteins have been detected in the serum of HIV-1 infected patients. Possibly, these proteins are released by infected/
apoptotic cells. Exogenous accessory regulatory HIV-1 proteins are able to enter macrophages and modulate cellular
machineries including those that affect viral transcription. Furthermore HIV-1 proteins, e.g., gp120, may exert their
effects by interacting with cell surface membrane receptors, especially chemokine co-receptors. By activating the
signaling pathways such as NF-kappaB, MAP kinase (MAPK) and JAK/STAT, HIV-1 proteins promote viral replication by
stimulating transcription from the long terminal repeat (LTR) in infected macrophages; they are also involved in
macrophage-mediated bystander T cell apoptosis. The role of HIV-1 proteins in the modulation of macrophage
signaling will be discussed in regard to the formation of viral reservoirs and macrophage-mediated T cell apoptosis
during HIV-1 infection.
HIV-1 infection is characterized by sustained activation
of the immune system. As macrophages, along with other
cell types, are permissive to HIV-1 infection, they may be
infected by the virus, resulting in signaling modulation
. Even uninfected macrophages may be activated by
the soluble gp120 HIV-1 protein, or gp120 virion, via sev-
eral signaling pathways. Additionally, soluble HIV-1 pro-
teins such as Nef, Tat, and Vpr have been detected in
serum of HIV-1 infected patients, possibly released by
infected/apoptotic cells. Soluble exogenous HIV-1 pro-
teins are able to enter macrophages and modulate both
cellular machinery and viral transcription. Deciphering
the signaling pathways involved in the activation of mac-
rophages in HIV infection is critical to a better under-
standing of AIDS pathogenesis as this could lead to
innovative therapeutic approaches.
HIV-1 Proteins and Macrophage Signaling
Nef is a 27-kDa myristylated protein which is expressed
early in the virus life cycle. Nef down-regulates the cell
surface expression of CD4, CD28, and MHC class I .
Nef also modulates several signaling pathways [3-8].
While Nef is not considered to be a secreted protein,
exogenous Nef has been detected in the sera of AIDS
patients and in cultures of HIV-1-infected cells . There
is increasing evidence of the ability of extracellular Nef to
activate signaling pathways in uninfected cells [9-13].
Indeed, Nef is internalized by MDMs and dendritic cells,
but not by T cells , when added to cell cultures [14-
16]. Recently, Qiao et al.  reported that Nef was inter-
nalized in B cells in vitro, thereby suppressing CD40-
dependent immunoglobulin class switching. The pres-
ence of Nef in the sera of HIV-infected patients at con-
centrations ranging from 1 to 10 ng/mL has also been
described . This concentration may be higher in the
lymphonodal germinal centers where virion-trapping
dendritic cells, as well as virion-infected CD4+ T cells
and macrophages, are densely packed [17,18]. Infected
cells may release Nef through a non-classical secretory
pathway or after lysis. Following this, bystander cells may
internalize Nef via endocytosis, pinocytosis or other yet-
* Correspondence: email@example.com
1 Department of Virology, UPRES 4266 Pathogens and Inflammation, IFR 133
INSERM, University of Franche-Comté, CHU Besançon, F-25030 Besançon,
Full list of author information is available at the end of the article
Herbein et al. Retrovirology 2010, 7:34
Page 2 of 13
unknown mechanisms. Regarding intracellular signaling
induced by Nef treatment of MDMs, it has been reported
that Nef modulates the expression of a significant num-
ber of genes as early as 2 hours after treatment . This
suggested that a prompt transcriptional cell reprogram-
ming induced by Nef leads to the synthesis and the
release of pro-inflammatory cytokines/chemokines,
which in turn, activate STAT1 and STAT3 signal trans-
ducers and transcription activators [20,21]. In line with
these results, Nef treatment of MDMs was reported to
induce rapid activation of IKK/NF-kB, MAPK and IRF-3
signalling pathways. Nef induces prompt phosphoryla-
tion of three MAPKs, i.e., ERK1/2, JNK, and p38
[13,22,23]. A Nef treatment as short as 15 minutes is able
to induce p38 phosphorylation, most likely due to rapid
recruitment and activation of p38 signaling upstream
intermediates. Exogenously added Nef induces rapid
phosphorylation of the transcription factor IRF-3, the
main regulator of IFN-β gene expression [24-26]. It has
also been shown to induce tyrosine phosphorylation of
STAT2, well known to be induced by type I IFN signaling,
at an early infection stage (8 to 16 h) .
Macrophage activation and production of pro-inflam-
matory cytokines by Nef involves NF-κB activation, espe-
cially its p50/p50 homodimeric
heterodimeric forms. This event leads to sustained LTR
activation [13,19,27]. The activation of NF-κB in mac-
rophages treated with exogenously added Nef occurs as
early as 2 hours after treatment [13,28]. NF-κB activation
in primary macrophages treated with recombinant Nef is
mediated via the canonical pathway, primarily involving
IKKβ phosphorylation . Furthermore, many of the
transcripts induced in macrophages treated by Nef are
encoded by genes regulated by κB-like responsive ele-
ments  (Figure 1). Therefore, there is evidence that
exogenously added Nef plays a critical role in "hijacking"
the NF-κB signaling pathway, most likely upstream of
IKK, as observed after endogenous expression in mac-
rophages . This observation is in line with the role of
Nef-mediated activation of NF-κB, which promotes HIV-
1 replication via both direct and cytokine-mediated
effects . Thus, in monocyte-derived macrophages,
recombinant Nef enhances the production of cytokines
such as macrophage inflammatory protein-1 alpha
(MIP1α), MIP1β, TNFα, IL-1β and IL-6 involved in the
inflammatory response (Figure 1). Additionally, features
observed in promonocytic cells and primary mac-
rophages following exposure to recombinant Nef are very
similar to those observed following TNFα treatment .
Both recombinant Nef and TNFα activate NF-κB, AP-1
and JNK. That recombinant Nef and TNFα activate these
signaling pathways suggests the two events might modu-
late the cellular machinery in a similar way. Therefore,
they may have the same effects on HIV-1 replication in
mononuclear phagocytes . Exogenous Nef may mod-
ulate intracellular signaling pathways downstream of the
TNFα receptors (TNFRs), and thus mimic the effects of
TNFα on primary macrophages .
HIV-1 Tat is a virally encoded transactivating protein
which plays a critical role in viral replication and is con-
served in genomes of primate lentiviruses [31,32]. Tat is a
HIV-1 protein reportedly detected in the sera of infected
Figure 1 HIV-1 proteins modulate signaling in the macrophage.
The HIV-1 proteins Nef, Tat, Vpr, and gp120 alter cell signaling path-
ways, both in infected and uninfected macrophages. The presence of
exogenous Nef, Tat and Vpr has been reported in sera of AIDS patients,
which have the ability to enter the cells. HIV-1 proteins activate multi-
ple transcription factors in macrophages including NF-κB, Sp-1 and AP-
1, which have binding sites in the long terminal repeat (LTR) of HIV-1.
The induction of these factors results in increased viral production. Fur-
thermore, the activation of these transcription factors enhances cy-
tokine production by macrophages primarily involved in AIDS
pathogenesis. TNF promoter is shown as a prototype containing bind-
ing sites of NF-κB, Sp-1, and AP-1. Exogenous Nef and Vpr may en-
hance Tat-mediated transcription in addition to their effect on
transcription factors. Moreover, the viral glycoprotein gp120 activates
MAPK in uninfected and infected cells, resulting in increased TNFα pro-
duction through ATF-2 binding sites of its promoter. Tat also stimu-
lates CXCR4/CCR5 surface co-receptor expression, thus enhancing
viral entry in cells. Besides LTR activation through transcription factors,
Vpr-induced cell cycle arrest facilitates LTR stimulation.
NF-? ?B, AP-1, Sp-1
Sp-1 Sp-1 Sp-1
NF-? ?B, AP-1, Sp-1
Herbein et al. Retrovirology 2010, 7:34
Page 3 of 13
patients as well as in the media of infected cells . This
suggests that it might have a role both as endogenous
modulator of cellular functions within infected cells and
act on bystander cells. Tat activates monocytes, mac-
rophages, and microglial cells.
Tat Action on monocytes, macrophages, and monocytic cell
The HIV-1 Tat protein is essential for efficient transcrip-
tion of viral genes and for viral replication. It also regu-
lates the expression of several cellular genes and
interferes with intracellular signaling [34,35]. The mature
protein has a variable size, ranging from 86 to 101 amino
acids. It is organized in functional domains required for
transactivation activity. The C-terminus contains an
RDG motif which mediates cell adhesion and Tat binding
to integrin receptors . Specific Tat binding has been
reported for at least three cell surface molecules includ-
ing heparin sulfate, beta-integrin and chemokine recep-
tors. Tat as well as peptides spanning its cysteine-rich
region compete with cognate ligands to bind CXCR4,
CCR2, and CCR3 chemokine receptors in primary
human monocytes and PBMCs. Tat has also been
reported to trigger Ca2+ mobilization in macrophages in a
concentration-dependent manner through CCR2 and
CCR3 [37,38]. Moreover, Tat induces the expression of
CCR3, CCR5 and CXCR4 in monocytes/macrophages in
a concentration-dependent manner, possibly promoting
HIV-1 infection . Finally, Tat has been shown to serve
as chemoattractant for monocytes, and pretreatment
with Tat enhanced the monocyte invasive properties
Functional consequences of Tat activation include
TNFα release from macrophages, monocytes and THP-1
monocytic cell lines . Tat-induced TNFα release was
dependent on NF-κB activation and mediated through
the activation of protein kinase A, phospholipase C (PLC)
and protein tyrosine kinase pathways . Transient
[Ca2+]i release was observed in macrophages through IP3
receptor-regulated intracellular Ca2+ stores . This Tat-
induced [Ca2+]i elevation was not dependent on extracel-
lular Ca2+ or caffeine-sensitive ryanodine receptor-regu-
lated intracellular Ca2+ stores but rather on the PLC,
protein kinase C (PKC) and Gi/0 protein pathways. Tat-
induced calcium signaling in macrophages leads to the
production of pro-inflammatory cytokines and chemok-
ines, possibly contributing to inflammation and HIV-1
Thus, Tat displays biological activities mimicking those
mediated by TNFα . HIV-1 Tat may induce the
expression of TNFα and various cytokines, including IL-
6, TNFβ and TGFβ as well as the expression of cytokine
receptors such as the IL-4 receptor [44-49]. Like TNFα,
Tat may activate NF-κB, AP-1 and MAPK, including c-
Jun N-terminal kinase/stress-activated protein kinase
(JNK/SAPK) . Tat activates NF-κB, JNK, and AP-1,
but not MEK . These results suggest that HIV-1 Tat
and TNFα act through different mechanisms and that
HIV-1 Tat does not activate all of the kinases involved in
TNFR signaling . In short, like Nef, Tat mimics the
effects of TNFα resulting in the enhancement of viral rep-
lication via activation of NF-κB, AP-1, JNK, and MAPK.
Action of Tat on microglia
Tat protein is actively produced and released in the cen-
tral nervous system (CNS) by infected cells . Elevated
Tat mRNA levels have been detected in the brain of AIDS
patients , where Tat is believed to play a significant
role in the pathogenesis of HAD through not only its
direct neurotoxicity, but also through the release of dele-
terious products in microglial cells . Although they
act as CNS macrophages, microglia cells differ in many
aspects from peripheral macrophages. Their morphologi-
cal and functional specificity responds to cell-cell con-
tacts and secreted factors from surrounding astrocytes
and neurons. The strict separation of microglia cells from
blood components is due to the blood brain barrier
(BBB). This results in a down-regulated "surveillance"
phenotype . Microglial cells are nevertheless able to
undergo activation and acquire typical macrophage func-
tions such as phagocytosis of microbes or apoptotic bod-
ies and the secretion of inflammatory or anti-
inflammatory mediators [56,57].
Tat activates microglia and impairs major molecular
mechanisms that normally prevent or shorten microglial
activation. As is the case in macrophages, Tat increases
microglial production of free radicals as well as pro-
inflammatory cytokines and chemokines [42,43,58,59].
Tat induction of NO and inducible NO synthase (iNOS)
is enhanced by IFN-γ . This suggests that Tat and
IFN-γ cooperatively contribute to the severity of brain
damage observed in brain tissues from AIDS patients and
animal HAD models.
The transcription factor NF-κB plays a central role in
the regulation of inflammatory gene expression and is
involved in most Tat-induced effects in microglial cul-
tures . In surveillance microglia, signals provided by
astrocytes actively contribute to NF-κB down-modula-
tion . Elevated immunoreactivity for p50/p65 het-
erodimer subunits was found in microglia and brain
macrophages of children with HIV encephalitis 
despite repression by the surrounding cells. Likewise,
nuclear staining for NF-κB in the perivascular microglia/
macrophages of deep white matter and basal ganglia cor-
related with the severity of HIV-associated dementia in
AIDS patients . Interestingly, Tat-induced formation
of free radicals in microglial cells occurs independently
from NF-κB activation [65,66], as lipid peroxidation and
oxidative stress still occur in microglial cultures exposed
to Tat in the presence of NF-κB inhibitors . Likewise,
Herbein et al. Retrovirology 2010, 7:34
Page 4 of 13
the pro-oxidant activities of Tat in the N9 microglial cell
line depend on MAP kinase activation . Additionally,
antioxidants abrogate oxidative stress rather than the
other Tat-induced functions such as IL-1β, NO, and
TNF-α production or IkBα degradation . Thus, Tat-
induced NF-κB activation in microglia may not require
the formation of free radicals, although oxidative stress is
contributive to its activation .
In different cell types, including macrophages and
microglia, Tat influences cell function by modifying Ca2+
homeostasis . Indeed, Tat possesses a cysteine-
cysteine-phenylalanine domain, enabling Tat to mimic
beta chemokine effects on both Ca2+ movements and
chemotaxis . In microglia, Ca2+ mobilization and cell
migration by Tat are sensitive to pertussis toxin (PTX),
but not cholera toxin. This observation supports the
involvement of Gi rather than Gs type proteins, as
expected for chemokine receptor stimulation . Fur-
thermore, cross-desensitization studies revealed CCR3
receptor involvement. Similar to findings in monocytes,
Tat-induced Ca2+ signals in human microglia are charac-
terized by rapid desensitization .
Nanomolar concentrations of recombinant Tat have
been shown to decrease in a dose- and time-dependent
manner, cAMP accumulation induced in microglial cul-
tures by the β-adrenergic receptor agonist isoproterenol,
or by forskolin, an activator of adenylyl cyclase . In
microglia, increased cAMP accumulation lowers poten-
tially neurotoxic pro-inflammatory molecules [70-76]
and promotes the production of neuroprotective or
immunosuppressive substances . Thus, Tat may inter-
fere with cAMP's control on microglial activation.
Among the ion channels expressed by microglial cells,
there are two major classes of K+-permeable channels:
the delayed-outward-rectifying (Kdr) and the inward-rec-
tifying (Kir) channels. Their expression differs in mac-
rophages and microglia. Their expression is finely
modulated by both activation and differentiation [77-81].
Chronic microglial cell treatment with high Tat concen-
tration (≥ 100 ng/mL) up-regulates Kdr currents due to
NF-κB-dependent increase in channel expression without
a significant increase in Kdr currents . Therefore, the
hyperpolarization thus induced by Tat may has several
consequences. Ca2+ influx depends on a hyperpolarized
membrane potential and Tat's β-chemokine mimicry may
thus be favored by Kdr currents. Kdr currents may also
modulate the microglial respiratory burst and the trans-
port of amino acids through voltage-dependent trans-
porters. The latter is likely to modify the availability of
amino acids for protein synthesis [83,84], as well as the
dynamics of glutamate exchange between intracellular
and extracellular pools. This may affect the regulation of
both extracellular glutamate concentration in the vicinity
of glutamate-sensitive neurons and glutathione synthesis
rate in microglia [85-87].
Vpr is a 96 amino acid-long virion-associated protein
located in the cytoplasm and nucleus of HIV-infected
cells [88-93]. Vpr is not essential for viral replication in T
cells, but critical for HIV replication in non-dividing cells
such as macrophages [94-99]. Vpr has pleiotropic effects
on viral replication, cellular proliferation and differentia-
tion, cytokine production, NF-κB-mediated transcription
and apoptosis [100-103].
Vpr has been shown to induce cell cycle arrest at the G2
cell cycle phase [104-107]. G2 cell cycle arrest correlates
with the inhibition of Cdc2 activity and parallels
enhanced viral replication [108-110]. G2 cell cycle arrest
is followed by apoptosis in HIV-infected and Vpr-
expressing cells . Apoptosis is mediated through the
interaction of Vpr with the mitochondrion permeability
transition pore. This interaction opens the pore, causing
mitochondrial swelling, release of cytochrome C as well
as caspase 9 and caspase 3 activation . p53 tumor
suppressor protein may be implicated in cell cycle arrest
and apoptosis mediated by Vpr in certain cell types .
Vpr transactivates the viral promoter and HIV-1 LTR
resulting in increased viral replication. The G2 cell cycle
arrest is concomitant with high levels of viral replication
in primary human CD4+ T cells. An interaction between
Vpr, Sp1 and TFIIB transcription factors is required for
Vpr-mediated transcriptional enhancement of HIV-1
Vpr-mediated transactivation necessitates intact NF-κB
sites and depends on Vpr's ability to stimulate p300/CBP
coactivator function, which promotes cooperative inter-
action between the RelA subunit of NF-κB and the cyclin
B1Cdc2 . A structural and functional interaction
between Vpr and Tat has been reported, synergistically
enhancing the transcriptional activity of the HIV-1 LTR
The activity of recombinant Vpr (rVpr) in macrophages
has been investigated. High concentrations of rVpr as
well as the carboxy-terminal Vpr peptide are cytotoxic to
macrophages. However, at low concentrations rVpr was
shown to enhance the activity of several transcription
factors including AP-1, c-Jun, and, NF-κB . Amino-
and carboxy-terminal Vpr peptides retained transcription
factor activation properties, albeit to a lesser extent than
with the full-length rVpr. Similarly to Vpr expressed in
infected cells, rVpr stimulated HIV-1 replication in
acutely infected primary macrophages. Furthermore,
reduced p24 production by macrophages infected with
Vpr-deficient virus could be rescued by adding rVpr to
culture medium . Exposure to rVpr also increased
transcription and p21/waf1 levels in macrophages .
Herbein et al. Retrovirology 2010, 7:34
Page 5 of 13
These Vpr effects on macrophages may reflect the mech-
anisms by which Vpr activates the HIV-1 LTR and
enhances virus replication in acutely and latently infected
cells . Although primarily considered to be a regula-
tor of viral promoter transactivation, transcription factor
activation may have significant effects on macrophage
cellular functions [117,118]. Additionally, macrophages
and PBLs produce less chemokines following recombi-
nant Vpr treatment. This observation suggests that Vpr
modulates cytokine production by interfering with NF-
κB-mediated transcription [119,120].
HIV-1 infects human T cells and monocytes/mac-
rophages through the interaction of gp120 with CD4 and
the CXCR4 or CCR5 co-receptor, which determines the
cellular tropism [121-131]. HIV-1 gp120 down-regulates
CD4 expression in primary human macrophages through
induction of endogenous TNFα [121,132-136]. Actually,
TNFα down-regulates both surface and total CD4 expres-
sion in primary human macrophages at the transcription
level [134,137-140]. TNFα inhibits R5 and R5/X4 HIV-1
entry into primary macrophages via downregulation of
both cell surface CD4 and CCR5 and via enhanced secre-
tion of CC-chemokines, MIP-1α, MIP-1β and RANTES
[129,137,141-146]. An iterative pretreatment of primary
macrophages with TNFα prior to HIV infection inhibits
HIV-1 replication in primary macrophages . The
inhibition of HIV-1 entry into primary macrophages fol-
lowing TNFα pretreatment involves TNFR2 and is medi-
ated by the secretion of CC-chemokines such as
RANTES, MIP-1α, and MIP-1β[140,141]. TNFα induces
the production of RANTES, MIP-1α, and MIP-1β, which
in turn down-regulate cell surface CCR5 expression on
primary macrophages, resulting in the inhibition of R5
HIV-1 entry [147-151]. In agreement with this observa-
tion RANTES inhibits HIV-1 envelope-mediated mem-
brane fusion in primary macrophages  and inhibits
the activity of the RANTES promoter containing four
NF-κB binding sites which is up-regulated by TNFα
Many studies conducted over the past two decades
have shown that besides infection, exposure of mac-
rophages to intact virions or soluble gp120 may exert var-
ious functional effects on macrophages, including
cytokine secretion activation [121,135,154]. However, the
specific pathways involved in gp120-induced responses
have only been defined recently. The presence of non-
infectious virion particles in excess of infectious virus, the
ability of gp120 to dissociate from the transmembrane
gp41 portion of Env as well as detection of circulating
gp120 in infected patients  have raised the question
of what biological activities this protein is involved in
aside from mediating infection. Such studies have dem-
onstrated the ability of gp120 to activate intracellular sig-
naling in multiple cell types as a result of its binding to
receptor/co-receptor complex. Although gp120-induced
signaling has been extensively investigated in CD4+ T
cells, gp120 has also been reported to activate intracellu-
lar signals in macrophages .
In primary human macrophages, both R5 and X4 gp120
induce calcium mobilization, although R5 gp120 elicited
higher peaks and more sustained elevations than X4
gp120 [157,158]. Single-cell patch-clamp recording com-
bined with pharmacological antagonists and current
reversal potential analysis identified the ion channels
associated with CCR5 and CXCR4 activation: chloride,
calcium-activated potassium, and non-selective cation
(NSC) channels . These responses to HIV-1 gp120
were mediated by chemokine receptors, but not by CD4,
since the responses to R5 Env were absent in mac-
rophages from patients lacking cell surface CCR5 expres-
sion (CCR5Δ 32); responses to X4 gp120 were inhibited
by a small molecule CXCR4 antagonist [157,159]. While
R5 and X4 gp120 generally induced similar signals
through CCR5 and CXCR4, respectively, certain differ-
ences were noted. R5 Env opened the calcium-activated
outward K+ channels more frequently than X4 gp120, and
induced Cl- currents of greater amplitude. Gp120,
instead of CXCR4 or CCR5 binding chemokines, acti-
vated the NSC channel .
In addition, gp120 has been shown to activate all three
MAPK family members (ERK1/2, JNK, and p38) in mac-
rophages. R5 gp120 triggered macrophage release of
MIP-1, MCP-1, and TNFα. The secretion of these prod-
ucts was blocked by small molecule inhibitors of ERK1/2
and p38 MAPKs [39,161].
The src kinases Lyn and Hck are highly expressed in
macrophages, and recent in vitro kinase assays demon-
strated that R5 gp120 and MIP-1β activated Lyn in mac-
rophages . Neither R5 gp120 nor MIP-1β activated
Lyn in macrophages derived from CCR5Δ 32 donors or in
cells treated with a small molecule CCR5 inhibitor, indi-
cating that Lyn activation was elicited through CCR5
receptor. Unlike Lyn, Hck activation did not occur in
response to gp120 or chemokine stimulation [162,163].
Both a Lyn-specific peptide pseudo-substrate inhibitor
and PP2, a broad src family kinase inhibitor, suppressed
gp120-induced TNFα production. These results are sug-
gestive of a signaling cascade initiated by gp120 through
CCR5, involving Lyn activation of the MAPK pathway,
resulting in gp120-induced TNFα release.
Several lines of evidence indicate that HIV-1 gp120/
chemokine receptor interactions activate PI3K in mac-
rophages [39,164]. This finding is based upon R5 gp120
activation of protein kinase B (PKB), a downstream target
for class I PI3K and a useful indirect indicator of its acti-
vation. Furthermore, several small molecule PI3K inhibi-
Herbein et al. Retrovirology 2010, 7:34
Page 6 of 13
tors blocked gp120-induced CCR5-mediated ERK1/2 and
p38 phosphorylation, as well as TNFα release. These
results not only suggest a role for PI3Ks in CCR5 signal-
ing but also indicate that, like Lyn, PI3K acts upstream of
MAPKs in the regulation of cytokine production through
this pathway . It is unclear which PI3K isoform is
involved in these R5 gp120-induced signals, and the rela-
tionship between PI3K and Lyn remains to be deter-
Besides chemokine receptors, interactions between
HIV-1 gp120 and CD4 stimulate signal transduction
pathways, such as activation of PKC, generation of PKC-
dependent phosphorylation of CD4, and activation of the
ERK/MAPK pathway, which in turn stimulates transcrip-
tion factors such as NF-kB, AP-1, and Elk-1, as well as
induction of cytokine and chemokine gene expression
[115,165-172]. Early inflammatory gene products such as
TNFα, may stimulate HIV-1 replication in the absence of
HIV-1 Tat protein. Thus, the activation of cellular signal-
ing pathways leading to the production of cytokine and
chemokine genes by HIV-1 gp120 could facilitate viral
replication in the early phases of the viral life cycle .
Proline-rich tyrosine kinase 2 (Pyk2) activation has
been suggested as a critical signalling mechanism for
integrin-mediated formation of adhesion contacts in
macrophages known as podosomes. Pyk2 is known to be
activated by chemokines, triggering cell migration
[173,174]. CCR5 and CXCR4 are both linked to Pyk2,
which is activated by R5 gp120 and MIP-1β as well as X4
gp120 and SDF-1α . Recently, a functional role for
Pyk2 in the migration of macrophages has been demon-
strated using Pyk2 knockout mice , suggesting that
gp120 may be involved in macrophage migration.
Macrophage Signaling and HIV-1 Pathogenesis
In this section, we report that several HIV-1 proteins may
modulate the macrophage signaling pathway resulting in
T lymphocytes depletion and viral cellular reservoir for-
mation, especially in macrophages .
Macrophage signaling and T cell apoptosis
Increased spontaneous and activation-induced apoptosis
of peripheral CD4+ T cells from HIV-infected patients is
observed ex vivo in lymph nodes of HIV-infected patients
and of SIV-infected macaques [177-180]. Deciphering the
molecular mechanisms involved in CD4+ T cell apoptosis
in HIV-infected patients is critical to understanding HIV
In macrophages, Nef has been shown to activate multi-
ple cellular pathways, possibly leading to increased infec-
tion of adjacent T cells through bystander mechanisms
involving T cell activation (Figure 2). It has been shown
that Nef-expressing macrophages enhance resting CD4+
T cell permissiveness through a complex cellular and sol-
uble interaction involving macrophages, B cells, and
CD4+ T cells . Nef expression within macrophages
via adenoviral vectors has been shown to induce the
secretion of soluble CD23 and ICAM, resulting in up-reg-
ulation of costimulatory B cell receptors, including CD22,
CD54, CD58, and CD80. This leads to T cell activation
upon interaction with B cells via these costimulatory
receptors, thus enabling the generation of non-produc-
tive or productive reservoirs, depending on the interac-
Furthermore, Nef has been reported to prevent Fas-
and TNF-receptor-mediated deaths observed in HIV-
infected T cells via interaction with the apoptosis signal
regulating kinase-1 (ASK-1). Nef inhibits ASK-1, caspase
3 and caspase 8 activation, resulting in apoptosis block-
ade in HIV-infected cells [181-184]. Apoptosis was mea-
sured in productively infected CD4+ T lymphocytes
using a reporter virus and a recombinant HIV infectious
clone expressing the green fluorescent protein (GFP) in
the presence and absence of autologous macrophages.
The survival of productively infected CD4+ T lympho-
cytes has been shown to require Nef expression and acti-
Figure 2 A model of HIV-1 pathogenesis based on interactions
between macrophages and T cells which account for increased
immune suppression and cellular virion reservoirs. a) Viral glyco-
protein gp120 activates the production of pro-inflammatory cytokines
and chemokines by macrophages, attracting T cells in the vicinity of
macrophages, thereby increasing the number of infected cells and fu-
eling the viral reservoirs. HIV-1 proteins Nef, Tat, and Vpr activate the
long terminal repeat (LTR) of HIV-1, resulting in sustained viral growth
while also activating anti-apoptotic pathways that favor viral persis-
tence and formation of viral reservoir. b) Viral protein Tat participates in
CD4+ T cell death through TRAIL secretion by HIV-1 infected mac-
rophages. Viral gp120 glycoproteins increase the expression of TNF
and TNFR on macrophages and T cells, leading to CD8+ T cell apopto-
sis. Thus, macrophage signaling using viral proteins accounts for both
viral persistence and immune suppression during HIV-1 infection.
CD4+T cell as viral
? Expression of
TNF and TNFR
? production of proinflammatory
cytokines & chemokines
CD8+ T cell Apoptosis
CD4+ T cell Apoptosis
T cell activation
Inhibition of apoptosis
Recruitment of T cells
? T cell infection
T cell activation
? T cell infection
b. Immune suppression
a. Viral reservoir
Herbein et al. Retrovirology 2010, 7:34
Page 7 of 13
vation by TNFα expressed on macrophage surface,
thereby participating in the formation and maintenance
of viral reservoirs in HIV-infected patients .
In addition to the macrophage-mediated formation of
T cell reservoirs, in vitro culture models demonstrate that
uninfected CD4+ T cells undergo apoptosis upon contact
with HIV-infected cells; for example mononuclear phago-
cytes . Macrophages play a major role in this pro-
cess, suggesting that apoptosis-inducing
expressed by macrophages mediate apoptosis of suscepti-
ble CD4+ T cells [159,185-187]. Activated macrophages
produce TNFα following HIV infection in vitro .
TNFα is released as a soluble factor or expressed on the
surface of macrophages under a membrane-bound form
that primarily targets TNFR2 rather than TNFR1
[188,189]. TNFR2 stimulation may trigger T cell apopto-
sis, especially in CD8+ T cells . TNFα and TNF
receptors are increased in HIV-infected patients and
inversely correlated with CD4+ T cell counts . TNFα
is expressed on the surface of activated macrophages, and
cell surface TNFR2 is not increased on CD4+ infected T
cells. Therefore, for the most part, the apoptosis of CD4+
T lymphocytes is mediated via Fas/Fas ligand interaction
[185,186,191]. TNFα causes death at a later stage than Fas
and may be transduced through TNFR2, which does not
contain homology to the Fas death domain and uses dif-
ferent signaling pathways than TNFR1 [115,185].
Recently, Tat has been reported to induce secretion of
soluble TNF-related apoptosis-induced ligand (TRAIL)
in human macrophages, leading to the death of bystander
CD4+ T lymphocytes . Thus, the production of
TRAIL by Tat-stimulated monocytes/macrophages is
likely to be an additional mechanism by which HIV-1
infection destroys uninfected bystander cells.
CD8+ T cell apoptosis during HIV infection has been
shown to result from the interaction between membrane-
bound TNFα expressed on the surface of activated mac-
rophages and TNFR2 expressed on the surface of acti-
vated CD8+ T cells . Both membrane-bound TNFα
and TNFR2 are up-regulated on macrophages and CD8+
T cells, respectively, following CXCR4 stimulation by
HIV gp120. However, CCR5 may also play a role, albeit
minor . TNFR2 stimulation of T cells results in
decreased intracellular levels of apoptosis protective pro-
tein Bcl-XL, a member of the Bcl-2 family . Impaired
induction of Bcl-XL has been observed in PBMC isolated
from HIV-infected patients . Therefore, TNFR2
stimulation of CD8+ T cells by membrane-bound TNFα
expressed on the surface of macrophages might decrease
the intracellular levels of anti-apoptotic proteins resulting
in CD8+ T cell death.
Additionally, chemokines and activated macrophages
have been reported to play a role in HIV-1 gp120-induced
neuronal apoptosis [194,195].
Macrophage signaling and formation of viral reservoirs
Whereas CD4+ T cells die within a few days after becom-
ing infected with HIV, infected macrophages seem to per-
sist for months, continuing to release viruses. Several
reasons may explain why macrophages are a major cellu-
lar reservoir of virions during infection (Figure 2). Mac-
rophages are more resistant than T cells to HIV-induced
apoptosis and therefore allow for sustained viral produc-
tion without fatal cell death. Persistent HIV infection of
macrophages results in increased NF-κB levels, involved
in the resistance to TNFα-induced apoptosis. Mac-
rophages release CC-chemokines which have the ability
to attract CD4+ and CD8+ T lymphocytes in their vicin-
ity . They may also block the entry of R5 HIV-1 viri-
ons into CD4+ target cells . CC-chemokine
production is often associated with that of pro-inflamma-
tory cytokines, such as TNFα and IL-1β, which stimulate
the transcription of HIV LTR via activation of NF-kB
[197,198]. Additionally, TNFα may block entry of R5
HIV-1 strains into macrophages via a decreased expres-
sion of CCR5 on cell surfaces [137,141,142,147]. Thus,
CC-chemokines and pro-inflammatory cytokines facili-
tate the recruitment and productive infection of CD4+ T
lymphocytes via increased viral transcription, while regu-
lating the entry of virions into macrophages, thereby pre-
venting macrophage superinfection.
apoptosis inhibition in HIV-1 infected T cells enhances
virus production and facilitates persistent infection .
HIV-1 proteins, by modulation of the TNFR signaling
pathway, lead to the formation of viral reservoirs, espe-
cially in primary macrophages . Altogether, the data
indicate that both viral and cellular factors are involved in
the controlled and sustained production of virions in
infected CD4+ T lymphocytes and macrophages, thereby
expanding the viral reservoir which fuels disease progres-
The macrophage is essential in the loss of T lymphocytes
and formation of viral reservoirs; it plays a critical role in
HIV-1 disease progression. Several HIV-1 proteins mod-
ulate signaling in infected and bystander macrophages,
thereby facilitating disease progression. A better under-
standing of the manner by which HIV-1 modulates sig-
naling in macrophages may be instrumental in the
development of new therapeutic approaches that may
ultimately restrict or decrease the size of cellular virion
reservoirs in HIV-1-infected patients.
The authors declare that they have no competing interests.
GH was responsible for drafting and revising the manuscript as well as organiz-
ing the content. GG was responsible for drafting and revising the section
Herbein et al. Retrovirology 2010, 7:34
Page 8 of 13
"Action of Tat on microglia". KAK created Figures 1 and 2. WA assisted in revising
This review is the result of a reflection conducted by the Association for Mac-
rophages and Infection Research (AMIR). The work of G. Herbein, W. Abbas, and
K.A. Khan was supported by institutional funding from Franche-Comté Univer-
sity. W. Abbas and K.A. Khan are supported by grants of the Higher Education
Committee of Pakistan. The group led by G. Gras was supported by grants from
the Agence nationale de recherche sur le sida et les hépatites virales, the Fondation
pour la recherche médicale and Ensemble contre le sida (Sidaction).
1Department of Virology, UPRES 4266 Pathogens and Inflammation, IFR 133
INSERM, University of Franche-Comté, CHU Besançon, F-25030 Besançon,
France and 2CEA, Institute of Emerging Diseases and Innovative Therapies,
Division of Immuno-Virology, Université Paris-Sud UMR E01, F-92265 Fontenay-
aux Roses, France
1. Coleman CM, Wu L: HIV interactions with monocytes and dendritic
cells: viral latency and reservoirs. Retrovirology 2009, 6:51.
2. Foster JL, Garcia JV: HIV-1 Nef: at the crossroads. Retrovirology 2008, 5:84.
3. Aiken C, Trono D: Nef stimulates human immunodeficiency virus type 1
proviral DNA synthesis. J Virol 1995, 69:5048-5056.
4. Bazan JF, Bacon KB, Hardiman G, Wang W, Soo K, Rossi D, Greaves DR,
Zlotnik A, Schall TJ: A new class of membrane-bound chemokine with a
CX3C motif. Nature 1997, 385:640-644.
5. Stein M, Keshav S, Harris N, Gordon S: Interleukin 4 potently enhances
murine macrophage mannose receptor activity: a marker of alternative
immunologic macrophage activation. J Exp Med 1992, 176:287-292.
6.Miller MD, Warmerdam MT, Gaston I, Greene WC, Feinberg MB: The
human immunodeficiency virus-1 nef gene product: a positive factor
for viral infection and replication in primary lymphocytes and
macrophages. J Exp Med 1994, 179:101-113.
7. Lama J, Mangasarian A, Trono D: Cell-surface expression of CD4 reduces
HIV-1 infectivity by blocking Env incorporation in a Nef- and Vpu-
inhibitable manner. Curr Biol 1999, 9:622-631.
8. Schwartz O, Marechal V, Le Gall S, Lemonnier F, Heard JM: Endocytosis of
major histocompatibility complex class I molecules is induced by the
HIV-1 Nef protein. Nat Med 1996, 2:338-342.
9. Fujii Y, Otake K, Tashiro M, Adachi A: Soluble Nef antigen of HIV-1 is
cytotoxic for human CD4+ T cells. FEBS Lett 1996, 393:93-96.
10. Brigino E, Haraguchi S, Koutsonikolis A, Cianciolo GJ, Owens U, Good RA,
Day NK: Interleukin 10 is induced by recombinant HIV-1 Nef protein
involving the calcium/calmodulin-dependent phosphodiesterase
signal transduction pathway. Proc Natl Acad Sci USA 1997, 94:3178-3182.
11. Qiao X, He B, Chiu A, Knowles DM, Chadburn A, Cerutti A: Human
immunodeficiency virus 1 Nef suppresses CD40-dependent
immunoglobulin class switching in bystander B cells. Nat Immunol
12. Tobiume M, Fujinaga K, Suzuki S, Komoto S, Mukai T, Ikuta K: Extracellular
Nef protein activates signal transduction pathway from Ras to
mitogen-activated protein kinase cascades that leads to activation of
human immunodeficiency virus from latency. AIDS Res Hum Retroviruses
13. Varin A, Manna SK, Quivy V, Decrion AZ, Van Lint C, Herbein G, Aggarwal
BB: Exogenous Nef protein activates NF-kappa B, AP-1, and c-Jun N-
terminal kinase and stimulates HIV transcription in promonocytic cells.
Role in AIDS pathogenesis. J Biol Chem 2003, 278:2219-2227.
14. Alessandrini L, Santarcangelo AC, Olivetta E, Ferrantelli F, d'Aloja P,
Pugliese K, Pelosi E, Chelucci C, Mattia G, Peschle C, Verani P, Federico M: T-
tropic human immunodeficiency virus (HIV) type 1 Nef protein enters
human monocyte-macrophages and induces resistance to HIV
replication: a possible mechanism of HIV T-tropic emergence in AIDS. J
Gen Virol 2000, 81:2905-2917.
15. Quaranta MG, Camponeschi B, Straface E, Malorni W, Viora M: Induction
of interleukin-15 production by HIV-1 nef protein: a role in the
proliferation of uninfected cells. Exp Cell Res 1999, 250:112-121.
16. Quaranta MG, Mattioli B, Spadaro F, Straface E, Giordani L, Ramoni C,
Malorni W, Viora M: HIV-1 Nef triggers Vav-mediated signaling pathway
leading to functional and morphological differentiation of dendritic
cells. FASEB J 2003, 17:2025-2036.
17. Kuster H, Opravil M, Ott P, Schlaepfer E, Fischer M, Gunthard HF, Luthy R,
Weber R, Cone RW: Treatment-induced decline of human
immunodeficiency virus-1 p24 and HIV-1 RNA in lymphoid tissue of
patients with early human immunodeficiency virus-1 infection. Am J
Pathol 2000, 156:1973-1986.
18. Soudeyns H, Rebai N, Pantaleo GP, Ciurli C, Boghossian T, Sekaly RP, Fauci
AS: The T cell receptor V beta repertoire in HIV-1 infection and disease.
Semin Immunol 1993, 5:175-185.
19. Olivetta E, Percario Z, Fiorucci G, Mattia G, Schiavoni I, Dennis C, Jager J,
Harris M, Romeo G, Affabris E, Federico M: HIV-1 Nef induces the release
of inflammatory factors from human monocyte/macrophages:
involvement of Nef endocytotic signals and NF-kappa B activation. J
Immunol 2003, 170:1716-1727.
20. Federico M, Percario Z, Olivetta E, Fiorucci G, Muratori C, Micheli A, Romeo
G, Affabris E: HIV-1 Nef activates STAT1 in human monocytes/
macrophages through the release of soluble factors. Blood 2001,
21. Percario Z, Olivetta E, Fiorucci G, Mangino G, Peretti S, Romeo G, Affabris E,
Federico M: Human immunodeficiency virus type 1 (HIV-1) Nef
activates STAT3 in primary human monocyte/macrophages through
the release of soluble factors: involvement of Nef domains interacting
with the cell endocytotic machinery. J Leukoc Biol 2003, 74:821-832.
22. Mangino G, Percario ZA, Fiorucci G, Vaccari G, Manrique S, Romeo G,
Federico M, Geyer M, Affabris E: In vitro treatment of human monocytes/
macrophages with myristoylated recombinant Nef of human
immunodeficiency virus type 1 leads to the activation of mitogen-
activated protein kinases, IkappaB kinases, and interferon regulatory
factor 3 and to the release of beta interferon. J Virol 2007, 81:2777-2791.
23. Schrager JA, Der Minassian V, Marsh JW: HIV Nef increases T cell ERK MAP
kinase activity. J Biol Chem 2002, 277:6137-6142.
24. Hiscott J, Pitha P, Genin P, Nguyen H, Heylbroeck C, Mamane Y, Algarte M,
Lin R: Triggering the interferon response: the role of IRF-3 transcription
factor. J Interferon Cytokine Res 1999, 19:1-13.
25. Sato M, Tanaka N, Hata N, Oda E, Taniguchi T: Involvement of the IRF
family transcription factor IRF-3 in virus-induced activation of the IFN-
beta gene. FEBS Lett 1998, 425:112-116.
26. Yoneyama M, Suhara W, Fukuhara Y, Fukuda M, Nishida E, Fujita T: Direct
triggering of the type I interferon system by virus infection: activation
of a transcription factor complex containing IRF-3 and CBP/p300.
EMBO J 1998, 17:1087-1095.
27. Kilareski EM, Shah S, Nonnemacher MR, Wigdahl B: Regulation of HIV-1
transcription in cells of the monocyte-macrophage lineage.
Retrovirology 2009, 6:118.
28. Herbein G, Varin A, Larbi A, Fortin C, Mahlknecht U, Fulop T, Aggarwal BB:
Nef and TNFalpha are coplayers that favor HIV-1 replication in
monocytic cells and primary macrophages. Curr HIV Res 2008,
29. Swingler S, Brichacek B, Jacque JM, Ulich C, Zhou J, Stevenson M: HIV-1
Nef intersects the macrophage CD40L signalling pathway to promote
resting-cell infection. Nature 2003, 424:213-219.
30. Mahlknecht U, Will J, Varin A, Hoelzer D, Herbein G: Histone deacetylase
3, a class I histone deacetylase, suppresses MAPK11-mediated
activating transcription factor-2 activation and represses TNF gene
expression. J Immunol 2004, 173:3979-3990.
31. Jones KA: Tat and the HIV-1 promoter. Curr Opin Cell Biol 1993, 5:461-468.
32. Jeang KT, Xiao H, Rich EA: Multifaceted activities of the HIV-1
transactivator of transcription, Tat. J Biol Chem 1999, 274:28837-28840.
33. Ensoli B, Buonaguro L, Barillari G, Fiorelli V, Gendelman R, Morgan RA,
Wingfield P, Gallo RC: Release, uptake, and effects of extracellular
human immunodeficiency virus type 1 Tat protein on cell growth and
viral transactivation. J Virol 1993, 67:277-287.
34. Noonan D, Albini A: From the outside in: extracellular activities of HIV
Tat. Adv Pharmacol 2000, 48:229-250.
Received: 25 September 2009 Accepted: 9 April 2010
Published: 9 April 2010
This article is available from: http://www.retrovirology.com/content/7/1/34© 2010 Herbein et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Retrovirology 2010, 7:34
Herbein et al. Retrovirology 2010, 7:34
Page 9 of 13
35. Gautier VW, Gu L, O'Donoghue N, Pennington S, Sheehy N, Hall WW: In
vitro nuclear interactome of the HIV-1 Tat protein. Retrovirology 2009,
36. Chang HK, Gallo RC, Ensoli B: Regulation of Cellular Gene Expression and
Function by the Human Immunodeficiency Virus Type 1 Tat Protein. J
Biomed Sci 1995, 2:189-202.
37. Albini A, Benelli R, Giunciuglio D, Cai T, Mariani G, Ferrini S, Noonan DM:
Identification of a novel domain of HIV tat involved in monocyte
chemotaxis. J Biol Chem 1998, 273:15895-15900.
38. Xiao H, Neuveut C, Tiffany HL, Benkirane M, Rich EA, Murphy PM, Jeang KT:
Selective CXCR4 antagonism by Tat: implications for in vivo expansion
of coreceptor use by HIV-1. Proc Natl Acad Sci USA 2000, 97:11466-11471.
39. Cardona AE, Pioro EP, Sasse ME, Kostenko V, Cardona SM, Dijkstra IM,
Huang D, Kidd G, Dombrowski S, Dutta R, Lee JC, Cook DN, Jung S, Lira SA,
Littman DR, Ransohoff RM: Control of microglial neurotoxicity by the
fractalkine receptor. Nat Neurosci 2006, 9:917-924.
40. Lafrenie RM, Wahl LM, Epstein JS, Hewlett IK, Yamada KM, Dhawan S: HIV-
1-Tat modulates the function of monocytes and alters their
interactions with microvessel endothelial cells. A mechanism of HIV
pathogenesis. J Immunol 1996, 156:1638-1645.
41. Lafrenie RM, Wahl LM, Epstein JS, Hewlett IK, Yamada KM, Dhawan S: HIV-
1-Tat protein promotes chemotaxis and invasive behavior by
monocytes. J Immunol 1996, 157:974-977.
42. Nimmerjahn A, Kirchhoff F, Helmchen F: Resting microglial cells are
highly dynamic surveillants of brain parenchyma in vivo. Science 2005,
43. Power C, McArthur JC, Nath A, Wehrly K, Mayne M, Nishio J, Langelier T,
Johnson RT, Chesebro B: Neuronal death induced by brain-derived
human immunodeficiency virus type 1 envelope genes differs
between demented and nondemented AIDS patients. J Virol 1998,
44. Puri RK, Aggarwal BB: Human immunodeficiency virus type 1 tat gene
up-regulates interleukin 4 receptors on a human B-lymphoblastoid cell
line. Cancer Res 1992, 52:3787-3790.
45. Rautonen J, Rautonen N, Martin NL, Wara DW: HIV type 1 Tat protein
induces immunoglobulin and interleukin 6 synthesis by uninfected
peripheral blood mononuclear cells. AIDS Res Hum Retroviruses 1994,
46. Sastry KJ, Reddy HR, Pandita R, Totpal K, Aggarwal BB: HIV-1 tat gene
induces tumor necrosis factor-beta (lymphotoxin) in a human B-
lymphoblastoid cell line. J Biol Chem 1990, 265:20091-20093.
47. Puri RK, Leland P, Aggarwal BB: Constitutive expression of human
immunodeficiency virus type 1 tat gene inhibits interleukin 2 and
interleukin 2 receptor expression in a human CD4+ T lymphoid (H9)
cell line. AIDS Res Hum Retroviruses 1995, 11:31-40.
48. Husain SR, Leland P, Aggarwal BB, Puri RK: Transcriptional up-regulation
of interleukin 4 receptors by human immunodeficiency virus type 1 tat
gene. AIDS Res Hum Retroviruses 1996, 12:1349-1359.
49. Lotz M, Clark-Lewis I, Ganu V: HIV-1 transactivator protein Tat induces
proliferation and TGF beta expression in human articular
chondrocytes. J Cell Biol 1994, 124:365-371.
50. Herbein G, Khan KA: Is HIV infection a TNF receptor signalling-driven
disease? Trends Immunol 2008, 29:61-67.
51. Kumar A, Manna SK, Dhawan S, Aggarwal BB: HIV-Tat protein activates c-
Jun N-terminal kinase and activator protein-1. J Immunol 1998,
52. Ensoli B, Buonaguro L, Barillari G, Fiorelli V, Gendelman R, Morgan RA,
Wingfield P, Gallo RC: Release, uptake, and effects of extracellular
human immunodeficiency virus type 1 Tat protein on cell growth and
viral transactivation. J Virol 1993, 67:277-287.
53. Nath A, Geiger J: Neurobiological aspects of human immunodeficiency
virus infection: neurotoxic mechanisms. Prog Neurobiol 1998, 54:19-33.
54. Ghafouri M, Amini S, Khalili K, Sawaya BE: HIV-1 associated dementia:
symptoms and causes. Retrovirology 2006, 3:28.
55. Ransohoff RM, Perry VH: Microglial physiology: unique stimuli,
specialized responses. Annu Rev Immunol 2009, 27:119-145.
56. Minghetti L, Levi G: Microglia as effector cells in brain damage and
repair: focus on prostanoids and nitric oxide. Prog Neurobiol 1998,
57. Streit WJ: Microglia and the response to brain injury. Ernst Schering Res
Found Workshop 2002:11-24.
58. Sheng WS, Hu S, Hegg CC, Thayer SA, Peterson PK: Activation of human
microglial cells by HIV-1 gp41 and Tat proteins. Clin Immunol 2000,
59. Sawaya BE, Thatikunta P, Denisova L, Brady J, Khalili K, Amini S: Regulation
of TNFalpha and TGFbeta-1 gene transcription by HIV-1 Tat in CNS
cells. J Neuroimmunol 1998, 87:33-42.
60. Polazzi E, Levi G, Minghetti L: Human immunodeficiency virus type 1 Tat
protein stimulates inducible nitric oxide synthase expression and nitric
oxide production in microglial cultures. J Neuropathol Exp Neurol 1999,
61. De Simone R, Ajmone-Cat MA, Minghetti L: Atypical antiinflammatory
activation of microglia induced by apoptotic neurons: possible role of
phosphatidylserine-phosphatidylserine receptor interaction. Mol
Neurobiol 2004, 29:197-212.
62. Rosenstiel P, Lucius R, Deuschl G, Sievers J, Wilms H: From theory to
therapy: implications from an in vitro model of ramified microglia.
Microsc Res Tech 2001, 54:18-25.
63. Dollard SC, James HJ, Sharer LR, Epstein LG, Gelbard HA, Dewhurst S:
Activation of nuclear factor kappa B in brains from children with HIV-1
encephalitis. Neuropathol Appl Neurobiol 1995, 21:518-528.
64. Rostasy K, Monti L, Yiannoutsos C, Wu J, Bell J, Hedreen J, Navia BA:
NFkappaB activation, TNF-alpha expression, and apoptosis in the
AIDS-Dementia-Complex. J Neurovirol 2000, 6:537-543.
65. Nicolini A, Ajmone-Cat MA, Bernardo A, Levi G, Minghetti L: Human
immunodeficiency virus type-1 Tat protein induces nuclear factor (NF)-
kappaB activation and oxidative stress in microglial cultures by
independent mechanisms. J Neurochem 2001, 79:713-716.
66. Bruce-Keller AJ, Barger SW, Moss NI, Pham JT, Keller JN, Nath A: Pro-
inflammatory and pro-oxidant properties of the HIV protein Tat in a
microglial cell line: attenuation by 17 beta-estradiol. J Neurochem 2001,
67. Bowie A, O'Neill LA: Oxidative stress and nuclear factor-kappaB
activation: a reassessment of the evidence in the light of recent
discoveries. Biochem Pharmacol 2000, 59:13-23.
68. Hegg CC, Hu S, Peterson PK, Thayer SA: Beta-chemokines and human
immunodeficiency virus type-1 proteins evoke intracellular calcium
increases in human microglia. Neuroscience 2000, 98:191-199.
69. Patrizio M, Colucci M, Levi G: Human immunodeficiency virus type 1 Tat
protein decreases cyclic AMP synthesis in rat microglia cultures. J
Neurochem 2001, 77:399-407.
70. Aloisi F, De Simone R, Columba-Cabezas S, Levi G: Opposite effects of
interferon-gamma and prostaglandin E2 on tumor necrosis factor and
interleukin-10 production in microglia: a regulatory loop controlling
microglia pro- and anti-inflammatory activities. J Neurosci Res 1999,
71. Aloisi F, Penna G, Cerase J, Menendez Iglesias B, Adorini L: IL-12
production by central nervous system microglia is inhibited by
astrocytes. J Immunol 1997, 159:1604-1612.
72. Caggiano AO, Kraig RP: Prostaglandin E receptor subtypes in cultured
rat microglia and their role in reducing lipopolysaccharide-induced
interleukin-1beta production. J Neurochem 1999, 72:565-575.
73. Davalos D, Grutzendler J, Yang G, Kim JV, Zuo Y, Jung S, Littman DR, Dustin
ML, Gan WB: ATP mediates rapid microglial response to local brain
injury in vivo. Nat Neurosci 2005, 8:752-758.
74. Minghetti L, Nicolini A, Polazzi E, Creminon C, Maclouf J, Levi G:
Prostaglandin E2 downregulates inducible nitric oxide synthase
expression in microglia by increasing cAMP levels. Adv Exp Med Biol
75. Minghetti L, Nicolini A, Polazzi E, Creminon C, Maclouf J, Levi G: Inducible
nitric oxide synthase expression in activated rat microglial cultures is
downregulated by exogenous prostaglandin E2 and by
cyclooxygenase inhibitors. Glia 1997, 19:152-160.
76. Takahashi K, Prinz M, Stagi M, Chechneva O, Neumann H: TREM2-
transduced myeloid precursors mediate nervous tissue debris
clearance and facilitate recovery in an animal model of multiple
sclerosis. PLoS Med 2007, 4:e124.
77. Mayr B, Montminy M: Transcriptional regulation by the
phosphorylation-dependent factor CREB. Nat Rev Mol Cell Biol 2001,
78. Kettenmann H, Hoppe D, Gottmann K, Banati R, Kreutzberg G: Cultured
microglial cells have a distinct pattern of membrane channels different
from peritoneal macrophages. J Neurosci Res 1990, 26:278-287.
Herbein et al. Retrovirology 2010, 7:34
Page 10 of 13
79. Korotzer AR, Cotman CW: Voltage-gated currents expressed by rat
microglia in culture. Glia 1992, 6:81-88.
80. Visentin S, Agresti C, Patrizio M, Levi G: Ion channels in rat microglia and
their different sensitivity to lipopolysaccharide and interferon-gamma.
J Neurosci Res 1995, 42:439-451.
81. Leone C, Le Pavec G, Meme W, Porcheray F, Samah B, Dormont D, Gras G:
Characterization of human monocyte-derived microglia-like cells. Glia
82. Visentin S, Levi G: Protein kinase C involvement in the resting and
interferon-gamma-induced K+ channel profile of microglial cells. J
Neurosci Res 1997, 47:233-241.
83. Visentin S, Renzi M, Levi G: Altered outward-rectifying K(+) current
reveals microglial activation induced by HIV-1 Tat protein. Glia 2001,
84. Cheeseman CI: Molecular mechanisms involved in the regulation of
amino acid transport. Prog Biophys Mol Biol 1991, 55:71-84.
85. Gras G, Porcheray F, Samah B, Leone C: The glutamate-glutamine cycle
as an inducible, protective face of macrophage activation. J Leukoc Biol
86. Porcheray F, Leone C, Samah B, Rimaniol AC, Dereuddre-Bosquet N, Gras
G: Glutamate metabolism in HIV-infected macrophages: implications
for the CNS. Am J Physiol Cell Physiol 2006, 291:C618-626.
87. Rimaniol AC, Mialocq P, Clayette P, Dormont D, Gras G: Role of glutamate
transporters in the regulation of glutathione levels in human
macrophages. Am J Physiol Cell Physiol 2001, 281:C1964-1970.
88. McArthur JC, Hoover DR, Bacellar H, Miller EN, Cohen BA, Becker JT,
Graham NM, McArthur JH, Selnes OA, Jacobson LP, et al.: Dementia in
AIDS patients: incidence and risk factors. Multicenter AIDS Cohort
Study. Neurology 1993, 43:2245-2252.
89. Emerman M: HIV-1, Vpr and the cell cycle. Curr Biol 1996, 6:1096-1103.
90. Dragic T, Litwin V, Allaway GP, Martin SR, Huang Y, Nagashima KA,
Cayanan C, Maddon PJ, Koup RA, Moore JP, Paxton WA: HIV-1 entry into
CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature
91. Subbramanian RA, Kessous-Elbaz A, Lodge R, Forget J, Yao XJ, Bergeron D,
Cohen EA: Human immunodeficiency virus type 1 Vpr is a positive
regulator of viral transcription and infectivity in primary human
macrophages. J Exp Med 1998, 187:1103-1111.
92. Vodicka MA, Koepp DM, Silver PA, Emerman M: HIV-1 Vpr interacts with
the nuclear transport pathway to promote macrophage infection.
Genes Dev 1998, 12:175-185.
93. Jacquot G, Le Rouzic E, David A, Mazzolini J, Bouchet J, Bouaziz S,
Niedergang F, Pancino G, Benichou S: Localization of HIV-1 Vpr to the
nuclear envelope: impact on Vpr functions and virus replication in
macrophages. Retrovirology 2007, 4:84.
94. Heinzinger NK, Bukinsky MI, Haggerty SA, Ragland AM, Kewalramani V,
Lee MA, Gendelman HE, Ratner L, Stevenson M, Emerman M: The Vpr
protein of human immunodeficiency virus type 1 influences nuclear
localization of viral nucleic acids in nondividing host cells. Proc Natl
Acad Sci USA 1994, 91:7311-7315.
95. Ogawa K, Shibata R, Kiyomasu T, Higuchi I, Kishida Y, Ishimoto A, Adachi A:
Mutational analysis of the human immunodeficiency virus vpr open
reading frame. J Virol 1989, 63:4110-4114.
96. Westervelt P, Henkel T, Trowbridge DB, Orenstein J, Heuser J, Gendelman
HE, Ratner L: Dual regulation of silent and productive infection in
monocytes by distinct human immunodeficiency virus type 1
determinants. J Virol 1992, 66:3925-3931.
97. Balotta C, Lusso P, Crowley R, Gallo RC, Franchini G: Antisense
phosphorothioate oligodeoxynucleotides targeted to the vpr gene
inhibit human immunodeficiency virus type 1 replication in primary
human macrophages. J Virol 1993, 67:4409-4414.
98. Balliet JW, Kolson DL, Eiger G, Kim FM, McGann KA, Srinivasan A, Collman
R: Distinct effects in primary macrophages and lymphocytes of the
human immunodeficiency virus type 1 accessory genes vpr, vpu, and
nef: mutational analysis of a primary HIV-1 isolate. Virology 1994,
99. Albright AV, Shieh JT, Itoh T, Lee B, Pleasure D, O'Connor MJ, Doms RW,
Gonzalez-Scarano F: Microglia express CCR5, CXCR4, and CCR3, but of
these, CCR5 is the principal coreceptor for human immunodeficiency
virus type 1 dementia isolates. J Virol 1999, 73:205-213.
100. Emerman M, Malim MH: HIV-1 regulatory/accessory genes: keys to
unraveling viral and host cell biology. Science 1998, 280:1880-1884.
101. Frankel AD, Young JA: HIV-1: fifteen proteins and an RNA. Annu Rev
Biochem 1998, 67:1-25.
102. Bukrinsky M, Adzhubei A: Viral protein R of HIV-1. Rev Med Virol 1999,
103. Stewart SA, Poon B, Song JY, Chen IS: Human immunodeficiency virus
type 1 vpr induces apoptosis through caspase activation. J Virol 2000,
104. He J, Choe S, Walker R, Di Marzio P, Morgan DO, Landau NR: Human
immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the
G2 phase of the cell cycle by inhibiting p34cdc2 activity. J Virol 1995,
105. Jowett JB, Planelles V, Poon B, Shah NP, Chen ML, Chen IS: The human
immunodeficiency virus type 1 vpr gene arrests infected T cells in the
G2 + M phase of the cell cycle. J Virol 1995, 69:6304-6313.
106. Re F, Braaten D, Franke EK, Luban J: Human immunodeficiency virus type
1 Vpr arrests the cell cycle in G2 by inhibiting the activation of
p34cdc2-cyclin B. J Virol 1995, 69:6859-6864.
107. Sawaya BE, Khalili K, Mercer WE, Denisova L, Amini S: Cooperative actions
of HIV-1 Vpr and p53 modulate viral gene transcription. J Biol Chem
108. Bartz SR, Rogel ME, Emerman M: Human immunodeficiency virus type 1
cell cycle control: Vpr is cytostatic and mediates G2 accumulation by a
mechanism which differs from DNA damage checkpoint control. J Virol
109. Yao XJ, Mouland AJ, Subbramanian RA, Forget J, Rougeau N, Bergeron D,
Cohen EA: Vpr stimulates viral expression and induces cell killing in
human immunodeficiency virus type 1-infected dividing Jurkat T cells.
J Virol 1998, 72:4686-4693.
110. Watanabe N, Yamaguchi T, Akimoto Y, Rattner JB, Hirano H, Nakauchi H:
Induction of M-phase arrest and apoptosis after HIV-1 Vpr expression
through uncoupling of nuclear and centrosomal cycle in HeLa cells.
Exp Cell Res 2000, 258:261-269.
111. Jacotot E, Ferri KF, El Hamel C, Brenner C, Druillennec S, Hoebeke J, Rustin
P, Metivier D, Lenoir C, Geuskens M, Vieira HL, Loeffler M, Belzacq AS,
Briand JP, Zamzami N, Edelman L, Xie ZH, Reed JC, Roques BP, Kroemer G:
Control of mitochondrial membrane permeabilization by adenine
nucleotide translocator interacting with HIV-1 viral protein rR and Bcl-
2. J Exp Med 2001, 193:509-519.
112. Gummuluru S, Emerman M: Cell cycle- and Vpr-mediated regulation of
human immunodeficiency virus type 1 expression in primary and
transformed T-cell lines. J Virol 1999, 73:5422-5430.
113. Wang L, Mukherjee S, Jia F, Narayan O, Zhao LJ: Interaction of virion
protein Vpr of human immunodeficiency virus type 1 with cellular
transcription factor Sp1 and trans-activation of viral long terminal
repeat. J Biol Chem 1995, 270:25564-25569.
114. Sawaya BE, Khalili K, Gordon J, Taube R, Amini S: Cooperative interaction
between HIV-1 regulatory proteins Tat and Vpr modulates
transcription of the viral genome. J Biol Chem 2000, 275:35209-35214.
115. Varin A, Decrion AZ, Sabbah E, Quivy V, Sire J, Van Lint C, Roques BP,
Aggarwal BB, Herbein G: Synthetic Vpr protein activates activator
protein-1, c-Jun N-terminal kinase, and NF-kappaB and stimulates HIV-
1 transcription in promonocytic cells and primary macrophages. J Biol
Chem 2005, 280:42557-42567.
116. Eckstein DA, Sherman MP, Penn ML, Chin PS, De Noronha CM, Greene WC,
Goldsmith MA: HIV-1 Vpr enhances viral burden by facilitating infection
of tissue macrophages but not nondividing CD4+ T cells. J Exp Med
117. Vazquez N, Greenwell-Wild T, Marinos NJ, Swaim WD, Nares S, Ott DE,
Schubert U, Henklein P, Orenstein JM, Sporn MB, Wahl SM: Human
immunodeficiency virus type 1-induced macrophage gene expression
includes the p21 gene, a target for viral regulation. J Virol 2005,
118. Muthumani K, Hwang DS, Choo AY, Mayilvahanan S, Dayes NS, Thieu KP,
Weiner DB: HIV-1 Vpr inhibits the maturation and activation of
macrophages and dendritic cells in vitro. Int Immunol 2005, 17:103-116.
119. Muthumani K, Kudchodkar S, Papasavvas E, Montaner LJ, Weiner DB,
Ayyavoo V: HIV-1 Vpr regulates expression of beta chemokines in
human primary lymphocytes and macrophages. J Leukoc Biol 2000,
120. Muthumani K, Hwang DS, Dayes NS, Kim JJ, Weiner DB: The HIV-1
accessory gene vpr can inhibit antigen-specific immune function. DNA
Cell Biol 2002, 21:689-695.
Herbein et al. Retrovirology 2010, 7:34
Page 11 of 13
121. Herbein G, Keshav S, Collin M, Montaner LJ, Gordon S: HIV-1 induces
tumour necrosis factor and IL-1 gene expression in primary human
macrophages independent of productive infection. Clin Exp Immunol
122. Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, Lusso P:
Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-
suppressive factors produced by CD8+ T cells. Science 1995,
123. Alkhatib G, Combadiere C, Broder CC, Feng Y, Kennedy PE, Murphy PM,
Berger EA: CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a
fusion cofactor for macrophage-tropic HIV-1. Science 1996,
124. Choe H, Farzan M, Sun Y, Sullivan N, Rollins B, Ponath PD, Wu L, Mackay CR,
LaRosa G, Newman W, Gerard N, Gerard C, Sodroski J: The beta-
chemokine receptors CCR3 and CCR5 facilitate infection by primary
HIV-1 isolates. Cell 1996, 85:1135-1148.
125. Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, Di Marzio P,
Marmon S, Sutton RE, Hill CM, Davis CB, Peiper SC, Schall TJ, Littman DR,
Landau NR: Identification of a major co-receptor for primary isolates of
HIV-1. Nature 1996, 381:661-666.
126. Liu Y, Hao W, Letiembre M, Walter S, Kulanga M, Neumann H, Fassbender
K: Suppression of microglial inflammatory activity by myelin
phagocytosis: role of p47-PHOX-mediated generation of reactive
oxygen species. J Neurosci 2006, 26:12904-12913.
127. Doranz BJ, Rucker J, Yi Y, Smyth RJ, Samson M, Peiper SC, Parmentier M,
Collman RG, Doms RW: A dual-tropic primary HIV-1 isolate that uses
fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as
fusion cofactors. Cell 1996, 85:1149-1158.
128. Schmidtmayerova H, Sherry B, Bukrinsky M: Chemokines and HIV
replication. Nature 1996, 382:767.
129. Wang J, Roderiquez G, Oravecz T, Norcross MA: Cytokine regulation of
human immunodeficiency virus type 1 entry and replication in human
monocytes/macrophages through modulation of CCR5 expression. J
Virol 1998, 72:7642-7647.
130. Verani A, Gras G, Pancino G: Macrophages and HIV-1: dangerous
liaisons. Mol Immunol 2005, 42:195-212.
131. Melikyan GB: Common principles and intermediates of viral protein-
mediated fusion: the HIV-1 paradigm. Retrovirology 2008, 5:111.
132. Bergamini A, Faggioli E, Bolacchi F, Gessani S, Cappannoli L, Uccella I,
Demin F, Capozzi M, Cicconi R, Placido R, Vendetti S, Colizzi GM, Rocchi G:
Enhanced production of tumor necrosis factor-alpha and interleukin-6
due to prolonged response to lipopolysaccharide in human
macrophages infected in vitro with human immunodeficiency virus
type 1. J Infect Dis 1999, 179:832-842.
133. Clouse KA, Cosentino LM, Weih KA, Pyle SW, Robbins PB, Hochstein HD,
Natarajan V, Farrar WL: The HIV-1 gp120 envelope protein has the
intrinsic capacity to stimulate monokine secretion. J Immunol 1991,
134. Karsten V, Gordon S, Kirn A, Herbein G: HIV-1 envelope glycoprotein
gp120 down-regulates CD4 expression in primary human
macrophages through induction of endogenous tumour necrosis
factor-alpha. Immunology 1996, 88:55-60.
135. Merrill JE, Koyanagi Y, Chen IS: Interleukin-1 and tumor necrosis factor
alpha can be induced from mononuclear phagocytes by human
immunodeficiency virus type 1 binding to the CD4 receptor. J Virol
136. Choe W, Volsky DJ, Potash MJ: Induction of rapid and extensive beta-
chemokine synthesis in macrophages by human immunodeficiency
virus type 1 and gp120, independently of their coreceptor phenotype.
J Virol 2001, 75:10738-10745.
137. Bailer RT, Lee B, Montaner LJ: IL-13 and TNF-alpha inhibit dual-tropic
HIV-1 in primary macrophages by reduction of surface expression of
CD4, chemokine receptors CCR5, CXCR4 and post-entry viral gene
expression. Eur J Immunol 2000, 30:1340-1349.
138. Faltynek CR, Finch LR, Miller P, Overton WR: Treatment with recombinant
IFN-gamma decreases cell surface CD4 levels on peripheral blood
monocytes and on myelomonocyte cell lines. J Immunol 1989,
139. Montaner LJ, Herbein G, Gordon S: Regulation of macrophage activation
and HIV replication. Adv Exp Med Biol 1995, 374:47-56.
140. Cotter RL, Zheng J, Che M, Niemann D, Liu Y, He J, Thomas E, Gendelman
HE: Regulation of human immunodeficiency virus type 1 infection,
beta-chemokine production, and CCR5 expression in CD40L-
stimulated macrophages: immune control of viral entry. J Virol 2001,
141. Herbein G, Montaner LJ, Gordon S: Tumor necrosis factor alpha inhibits
entry of human immunodeficiency virus type 1 into primary human
macrophages: a selective role for the 75-kilodalton receptor. J Virol
142. Herbein G, Gordon S: 55- and 75-kilodalton tumor necrosis factor
receptors mediate distinct actions in regard to human
immunodeficiency virus type 1 replication in primary human
macrophages. J Virol 1997, 71:4150-4156.
143. Meylan PR, Guatelli JC, Munis JR, Richman DD, Kornbluth RS: Mechanisms
for the inhibition of HIV replication by interferons-alpha, -beta, and -
gamma in primary human macrophages. Virology 1993, 193:138-148.
144. Zaitseva M, Lee S, Lapham C, Taffs R, King L, Romantseva T, Manischewitz
J, Golding H: Interferon gamma and interleukin 6 modulate the
susceptibility of macrophages to human immunodeficiency virus type
1 infection. Blood 2000, 96:3109-3117.
145. Cremer I, Vieillard V, De Maeyer E: Retrovirally mediated IFN-beta
transduction of macrophages induces resistance to HIV, correlated
with up-regulation of RANTES production and down-regulation of C-C
chemokine receptor-5 expression. J Immunol 2000, 164:1582-1587.
146. Hewson TJ, Logie JJ, Simmonds P, Howie SE: A CCR5-dependent novel
mechanism for type 1 HIV gp120 induced loss of macrophage cell
surface CD4. J Immunol 2001, 166:4835-4842.
147. Lane BR, Markovitz DM, Woodford NL, Rochford R, Strieter RM, Coffey MJ:
TNF-alpha inhibits HIV-1 replication in peripheral blood monocytes
and alveolar macrophages by inducing the production of RANTES and
decreasing C-C chemokine receptor 5 (CCR5) expression. J Immunol
148. Coffey MJ, Woffendin C, Phare SM, Strieter RM, Markovitz DM: RANTES
inhibits HIV-1 replication in human peripheral blood monocytes and
alveolar macrophages. Am J Physiol 1997, 272:L1025-1029.
149. Jiang Y, Jolly PE: Effect of beta-chemokines on human
immunodeficiency virus type 1 replication, binding, uncoating, and
CCR5 receptor expression in human monocyte-derived macrophages.
J Hum Virol 1999, 2:123-132.
150. Capobianchi MR, Abbate I, Antonelli G, Turriziani O, Dolei A, Dianzani F:
Inhibition of HIV type 1 BaL replication by MIP-1alpha, MIP-1beta, and
RANTES in macrophages. AIDS Res Hum Retroviruses 1998, 14:233-240.
151. Ylisastigui L, Amzazi S, Bakri Y, Vizzavona J, Vita C, Gluckman JC, Benjouad
A: Effect of RANTES on the infection of monocyte-derived primary
macrophages by human immunodeficiency virus type 1 and type 2.
Biomedicine & Pharmacotherapy 1998, 52:447-453.
152. Stantchev TS, Broder CC: Consistent and significant inhibition of human
immunodeficiency virus type 1 envelope-mediated membrane fusion
by beta-chemokines (RANTES) in primary human macrophages. J
Infect Dis 2000, 182:68-78.
153. Moriuchi H, Moriuchi M, Fauci AS: Nuclear factor-kappa B potently up-
regulates the promoter activity of RANTES, a chemokine that blocks
HIV infection. J Immunol 1997, 158:3483-3491.
154. Wahl LM, Corcoran ML, Pyle SW, Arthur LO, Harel-Bellan A, Farrar WL:
Human immunodeficiency virus glycoprotein (gp120) induction of
monocyte arachidonic acid metabolites and interleukin 1. Proc Natl
Acad Sci USA 1989, 86:621-625.
155. Klasse PJ, Moore JP: Is there enough gp120 in the body fluids of HIV-1-
infected individuals to have biologically significant effects? Virology
156. Yi Y, Lee C, Liu QH, Freedman BD, Collman RG: Chemokine receptor
utilization and macrophage signaling by human immunodeficiency
virus type 1 gp120: Implications for neuropathogenesis. J Neurovirol
2004, 10(Suppl 1):91-96.
157. Liu QH, Williams DA, McManus C, Baribaud F, Doms RW, Schols D, De
Clercq E, Kotlikoff MI, Collman RG, Freedman BD: HIV-1 gp120 and
chemokines activate ion channels in primary macrophages through
CCR5 and CXCR4 stimulation. Proc Natl Acad Sci USA 2000, 97:4832-4837.
158. Herbein G, Mahlknecht U, Batliwalla F, Gregersen P, Pappas T, Butler J,
O'Brien WA, Verdin E: Apoptosis of CD8+ T cells is mediated by
macrophages through interaction of HIV gp120 with chemokine
receptor CXCR4. Nature 1998, 395:189-194.
159. Decrion AZ, Varin A, Estavoyer JM, Herbein G: CXCR4-Mediated T Cell
Apoptosis in HIV infection. Journal of General Virology 2004, 85:1471-8.
Herbein et al. Retrovirology 2010, 7:34
Page 12 of 13
160. Kenakin T: Ligand-selective receptor conformations revisited: the
promise and the problem. Trends Pharmacol Sci 2003, 24:346-354.
161. Del Corno M, Liu QH, Schols D, de Clercq E, Gessani S, Freedman BD,
Collman RG: HIV-1 gp120 and chemokine activation of Pyk2 and
mitogen-activated protein kinases in primary macrophages mediated
by calcium-dependent, pertussis toxin-insensitive chemokine receptor
signaling. Blood 2001, 98:2909-2916.
162. Tomkowicz B, Lee C, Ravyn V, Cheung R, Ptasznik A, Collman RG: The Src
kinase Lyn is required for CCR5 signaling in response to MIP-1beta and
R5 HIV-1 gp120 in human macrophages. Blood 2006, 108:1145-1150.
163. Lynch GW, Turville S, Carter B, Sloane AJ, Chan A, Muljadi N, Li S, Low L,
Armati P, Raison R, Zoellner H, Williamson P, Cunningham A, Church WB:
Marked differences in the structures and protein associations of
lymphocyte and monocyte CD4: resolution of a novel CD4 isoform.
Immunol Cell Biol 2006, 84:154-165.
164. Chugh P, Bradel-Tretheway B, Monteiro-Filho CM, Planelles V, Maggirwar
SB, Dewhurst S, Kim B: Akt inhibitors as an HIV-1 infected macrophage-
specific anti-viral therapy. Retrovirology 2008, 5:11.
165. Benkirane M, Jeang KT, Devaux C: The cytoplasmic domain of CD4 plays
a critical role during the early stages of HIV infection in T-cells. Embo J
166. Briant L, Coudronniere N, Robert-Hebmann V, Benkirane M, Devaux C:
Binding of HIV-1 virions or gp120-anti-gp120 immune complexes to
HIV-1-infected quiescent peripheral blood mononuclear cells reveals
latent infection. J Immunol 1996, 156:3994-4004.
167. Briant L, Robert-Hebmann V, Acquaviva C, Pelchen-Matthews A, Marsh M,
Devaux C: The protein tyrosine kinase p56lck is required for triggering
NF-kappaB activation upon interaction of human immunodeficiency
virus type 1 envelope glycoprotein gp120 with cell surface CD4. J Virol
168. Chirmule N, Kalyanaraman VS, Pahwa S: Signals transduced through the
CD4 molecule on T lymphocytes activate NF-kappa B. Biochem Biophys
Res Commun 1994, 203:498-505.
169. Popik W, Pitha PM: Binding of human immunodeficiency virus type 1 to
CD4 induces association of Lck and Raf-1 and activates Raf-1 by a Ras-
independent pathway. Mol Cell Biol 1996, 16:6532-6541.
170. Popik W, Hesselgesser JE, Pitha PM: Binding of human
immunodeficiency virus type 1 to CD4 and CXCR4 receptors
differentially regulates expression of inflammatory genes and activates
the MEK/ERK signaling pathway. J Virol 1998, 72:6406-6413.
171. Schmid-Antomarchi H, Benkirane M, Breittmayer V, Husson H, Ticchioni M,
Devaux C, Rossi B: HIV induces activation of phosphatidylinositol 4-
kinase and mitogen-activated protein kinase by interacting with T cell
CD4 surface molecules. Eur J Immunol 1996, 26:717-720.
172. Biard-Piechaczyk M, Robert-Hebmann V, Richard V, Roland J, Hipskind RA,
Devaux C: Caspase-dependent apoptosis of cells expressing the
chemokine receptor CXCR4 is induced by cell membrane-associated
human immunodeficiency virus type 1 envelope glycoprotein (gp120).
Virology 2000, 268:329-344.
173. Duong LT, Rodan GA: PYK2 is an adhesion kinase in macrophages,
localized in podosomes and activated by beta(2)-integrin ligation. Cell
Motil Cytoskeleton 2000, 47:174-188.
174. Davis CB, Dikic I, Unutmaz D, Hill CM, Arthos J, Siani MA, Thompson DA,
Schlessinger J, Littman DR: Signal transduction due to HIV-1 envelope
interactions with chemokine receptors CXCR4 or CCR5. J Exp Med 1997,
175. Okigaki M, Davis C, Falasca M, Harroch S, Felsenfeld DP, Sheetz MP,
Schlessinger J: Pyk2 regulates multiple signaling events crucial for
macrophage morphology and migration. Proc Natl Acad Sci USA 2003,
176. Herbein G, Coaquette A, Perez-Bercoff D, Pancino G: Macrophage
activation and HIV infection: can the Trojan horse turn into a fortress?
Curr Mol Med 2002, 2:723-738.
177. Finkel TH, Tudor-Williams G, Banda NK, Cotton MF, Curiel T, Monks C, Baba
TW, Ruprecht RM, Kupfer A: Apoptosis occurs predominantly in
bystander cells and not in productively infected cells of HIV- and SIV-
infected lymph nodes. Nat Med 1995, 1:129-134.
178. Katsikis PD, Garcia-Ojeda ME, Torres-Roca JF, Greenwald DR, Herzenberg
LA: HIV type 1 Tat protein enhances activation-but not Fas (CD95)-
induced peripheral blood T cell apoptosis in healthy individuals. Int
Immunol 1997, 9:835-841.
179. Groux H, Torpier G, Monte D, Mouton Y, Capron A, Ameisen JC:
Activation-induced death by apoptosis in CD4+ T cells from human
immunodeficiency virus-infected asymptomatic individuals. J Exp Med
180. Oyaizu N, McCloskey TW, Coronesi M, Chirmule N, Kalyanaraman VS,
Pahwa S: Accelerated apoptosis in peripheral blood mononuclear cells
(PBMCs) from human immunodeficiency virus type-1 infected patients
and in CD4 cross-linked PBMCs from normal individuals. Blood 1993,
181. Geleziunas R, Xu W, Takeda K, Ichijo H, Greene WC: HIV-1 Nef inhibits
ASK1-dependent death signalling providing a potential mechanism
for protecting the infected host cell. Nature 2001, 410:834-838.
182. Yoon K, Jeong JG, Kim S: Stable expression of human immunodeficiency
virus type 1 Nef confers resistance against Fas-mediated apoptosis.
AIDS Res Hum Retroviruses 2001, 17:99-104.
183. Mahlknecht U, Herbein G: Macrophages and T-cell apoptosis in HIV
infection: a leading role for accessory cells? Trends Immunol 2001,
184. Mahlknecht U, Deng C, Lu MC, Greenough TC, Sullivan JL, O'Brien WA,
Herbein G: Resistance to apoptosis in HIV-infected CD4+ T
lymphocytes is mediated by macrophages: role for Nef and immune
activation in viral persistence. J Immunol 2000, 165:6437-6446.
185. Badley AD, McElhinny JA, Leibson PJ, Lynch DH, Alderson MR, Paya CV:
Upregulation of Fas ligand expression by human immunodeficiency
virus in human macrophages mediates apoptosis of uninfected T
lymphocytes. J Virol 1996, 70:199-206.
186. Badley AD, Dockrell D, Simpson M, Schut R, Lynch DH, Leibson P, Paya CV:
Macrophage-dependent apoptosis of CD4+ T lymphocytes from HIV-
infected individuals is mediated by FasL and tumor necrosis factor. J
Exp Med 1997, 185:55-64.
187. Gendelman HE, Orenstein JM, Baca LM, Weiser B, Burger H, Kalter DC,
Meltzer MS: The macrophage in the persistence and pathogenesis of
HIV infection. Aids 1989, 3:475-495.
188. Zheng L, Fisher G, Miller RE, Peschon J, Lynch DH, Lenardo MJ: Induction
of apoptosis in mature T cells by tumour necrosis factor. Nature 1995,
189. Grell M, Douni E, Wajant H, Lohden M, Clauss M, Maxeiner B,
Georgopoulos S, Lesslauer W, Kollias G, Pfizenmaier K: The
transmembrane form of tumor necrosis factor is the prime activating
ligand of the 80 kDa tumor necrosis factor receptor. Cell 1995,
190. Lahdevirta J, Maury CP, Teppo AM, Repo H: Elevated levels of circulating
cachectin/tumor necrosis factor in patients with acquired
immunodeficiency syndrome. Am J Med 1988, 85:289-291.
191. Poonia B, Pauza CD, Salvato MS: Role of the Fas/FasL pathway in HIV or
SIV disease. Retrovirology 2009, 6:91.
192. Galea I, Palin K, Newman TA, Van Rooijen N, Perry VH, Boche D: Mannose
receptor expression specifically reveals perivascular macrophages in
normal, injured, and diseased mouse brain. Glia 2005, 49:375-384.
193. Blair PJ, Boise LH, Perfetto SP, Levine BL, McCrary G, Wagner KF, St Louis
DC, Thompson CB, Siegel JN, June CH: Impaired induction of the
apoptosis-protective protein Bcl-xL in activated PBMC from
asymptomatic HIV-infected individuals. J Clin Immunol 1997,
194. Kaul M, Lipton SA: Chemokines and activated macrophages in HIV
gp120-induced neuronal apoptosis. Proc Natl Acad Sci USA 1999,
195. Wu DT, Woodman SE, Weiss JM, McManus CM, D'Aversa TG, Hesselgesser
J, Major EO, Nath A, Berman JW: Mechanisms of leukocyte trafficking
into the CNS. J Neurovirol 2000, 6(Suppl 1):S82-85.
196. Swingler S, Mann A, Jacque J, Brichacek B, Sasseville VG, Williams K,
Lackner AA, Janoff EN, Wang R, Fisher D, Stevenson M: HIV-1 Nef
mediates lymphocyte chemotaxis and activation by infected
macrophages. Nat Med 1999, 5:997-103.
197. Smit TK, Wang B, Ng T, Osborne R, Brew B, Saksena NK: Varied tropism of
HIV-1 isolates derived from different regions of adult brain cortex
discriminate between patients with and without AIDS dementia
complex (ADC): evidence for neurotropic HIV variants. Virology 2001,
198. Duh EJ, Maury WJ, Folks TM, Fauci AS, Rabson AB: Tumor necrosis factor
alpha activates human immunodeficiency virus type 1 through
Herbein et al. Retrovirology 2010, 7:34 Download full-text
Page 13 of 13
induction of nuclear factor binding to the NF-kappa B sites in the long
terminal repeat. Proc Natl Acad Sci USA 1989, 86:5974-5978.
199. Antoni BA, Sabbatini P, Rabson AB, White E: Inhibition of apoptosis in
human immunodeficiency virus-infected cells enhances virus
production and facilitates persistent infection. J Virol 1995,
Cite this article as: Herbein et al., Macrophage signaling in HIV-1 infection
Retrovirology 2010, 7:34